The Global RivaroxabanMarket, by Strength (10 mg, 15 mg, and 20 mg), by Application (Deep VeinThrombosis Prophylaxis and Pulmonary Embolism), by Distribution Channel(Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)is estimated to be valued at US$ 5,653 million in 2017 and is projected toexhibit a CAGR of 1.5% over the forecast period (2018 – 2026). The API patentis set to expire in 2020 and product patent in 2023 leading to anticipatedprice erosion if the drug. Rivaroxaban is an oral anticoagulant, which wasdeveloped by Bayer and sold under the brand name Xarelto. The drug is indicatedfor the treatment of deep vein thrombosis prophylaxis or pulmonary embolism andto reduce the risk of stroke and systemic embolism in patients with non-valvularatrial fibrillation (AF).
The drug is marketed by Bayeroutside the U.S. and in the U.S., it is marketed by Janssen Pharmaceuticals,Inc. Xarelto is among the most popular anticoagulants, which includes brandslike Caumadin, Praxada, and Eliquis. The trajectory growth of rivaroxabanmarket can be attributed to increasing clinical trials by companies anduniversities to expand the indication of the drug or to use in combination withother drug. For instance, the University Hospital Inselspital, Berne, incollaboration with Bayer and Janssen, and two others, are studying the efficacyof rivaroxaban in patients undergoing bariatric surgery and as on May 2018, thetrial was under phase II.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1962
Browse Market Data 22 Tables and20 Figures spread through 150 Pages and in-depth TOC on ‘Rivaroxaban Market, byStrength (10 mg, 15 mg, and 20 mg), by Application (Deep Vein ThrombosisProphylaxis and Pulmonary Embolism), by Distribution Channel (HospitalsPharmacies, Retail Pharmacies, and Online Pharmacies) and by Region - GlobalForecast to 2026’ To know the latest trends and insights related to rivaroxabanmarket,
The market players of rivaroxabanmarket are also concentrating on enhancing effectiveness and reducing the sideeffects such as bleeding of the drug. For instance, as of June 2018, JanssenScientific Affairs, LLC is studying the effectiveness of Xarelto with a mobileadherence platform, to improve medication adherence in patients with atrialfibrillation. However, the presence of cheaper alternative drugs such aswarfarin, apixaban, and dabigatran are expected to be major factors hindering therivaroxaban market growth. The treatment cost using warfarin is as low as US$ 4per month whereas the cost of rivaroxaban is around US$ 450 per month. Thisvast difference in cost of the drug lead the patients towards adopting cheaperalternative, thereby negatively affecting the market growth.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/rivaroxaban-market-1962
Key takeaways of the RivaroxabanMarket:
The global rivaroxaban market isexpected to expand at a CAGR of 1.5% over the forecast period (2018 – 2026),owing to increasing clinical trials
High cost of rivaroxaban therapycompared to it alternatives may restrain the market growth
Patent expiration leading tomanufacturing of generics is expected to pose challenge to the Xarelto brandand may result in price reduction
Some of the major playersoperating in the global rivaroxaban market include Janssen Pharmaceuticals Inc.and Bayer AG.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1962
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
